Treatment Sequencing & Twice-Yearly Dosing [BACKUP]

[BACKUP SEGMENT] Dr. Muley frames two use cases: (1) Early use (<1 year disease duration) to intercept long-lived plasma cell formation and potentially reduce steroid/immunosuppressant reliance; (2) Later use in patients who have failed steroids, conventional ISTs, or downstream therapies (FcRn inhibitors, complement inhibitors). He discusses how upstream B cell suppression may allow tapering of downstream therapies, and how downstream therapies can bridge until inebilizumab takes effect if needed. Twice-yearly maintenance dosing highlighted as a practical consideration in minimizing treatment burden.

Note: Filmed as a backup to extend runtime -- not part of the original discussion guide.